TMCnet News
e-Therapeutics Announces Temporary Halt of Recruitment into ETS2101 Cancer Trials Because of Drug Supply IssueOXFORD & NEWCASTLE, England --(Business Wire)-- e-Therapeutics plc (AIM:ETX) today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials. Patients already receiving treatment with ETS2101 will continue to be dosed in accordance with trial protocols. Relevant regulators are being notified and the Company is taking steps to enable recruitment to resume as soon as possible. Two phase I studies of ETS2101 are ongoing: an investigator-led study in brain cancer at the UC San Diego Moores Cancer Center in La Jolla, California and a study at three UK centres that is enrolling patients with a variety of solid tumours. A report of ata from the UK study had been expected in Q1 2014; this may be delayed by the temporary halt in recruitment. About ETS2101 ETS2101 (dexanabinol) is a synthetic cannabinoid previously studied in trauma patients. Application of network pharmacology by e-Therapeutics suggested that the drug has potential in cancer. Preclinical studies then provided evidence of activity in a wide variety of cancer cell lines. Two phase I studies of ETS2101 are ongoing, one in patients with primary or secondary brain cancers and one in patients with various advanced solid tumours. About e-Therapeutics e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
|
